LncRNA-536 and RNA-Binding Protein RBM25 Interactions in Pulmonary Artery Smooth Muscle Cells: Implications in...

Area of Science:

• Molecular Biology
• Cardiovascular Research
• RNA Biology

Background:

• Pulmonary hypertension (PH) involves abnormal smooth muscle cell proliferation.
• The role of long noncoding RNAs (lncRNAs) in PH pathogenesis is increasingly recognized.
• Understanding the molecular mechanisms underlying PH is crucial for developing effective treatments.

Purpose of the Study:

• To elucidate the mechanistic association between lnc-536 and HOXB13 in PH.
• To investigate the role of lnc-536 in regulating pulmonary arterial smooth muscle cell (PASMC) phenotype.
• To explore the potential of targeting lnc-536 for PH therapy.

Main Methods:

• In vitro studies: lnc-536 knockdown/knockin, RNA pull-down, immunoprecipitation in PASMCs.
• In vivo studies: lnc-536 antisense oligos administration in pulmonary hypertensive rats.
• Analysis of lnc-536 and HOXB13 levels in patient-derived PASMCs.

Main Results:

• Increased lnc-536 downregulates tumor suppressor HOXB13, promoting PASMC proliferation.
• lnc-536 interacts with RBM25, which sequesters SFPQ, reducing HOXB13 expression.
• Inhibition of lnc-536 in vivo reversed PH markers and increased HOXB13 expression.
• Elevated lnc-536 and reduced HOXB13 found in idiopathic PAH-PASMCs.

Conclusions:

• Lnc-536 acts as a molecular decoy, disrupting the SFPQ-HOXB13 complex and promoting PASMC hyperproliferation.
• This mechanism involves regulation of Wnt and Hippo signaling pathways in idiopathic pulmonary arterial hypertension (PAH).
• Targeting lnc-536 demonstrates therapeutic efficacy in preclinical models of PH.